参考文献/References:
[1]杜霞，刁波.多形性胶质母细胞瘤的免疫治疗 [J].中国临床神经外科杂志， 2017，22（7）：514-516.
[2] Montserrat LV, Rawan AK, Stephanie J, et al. Advances in brain tumor surgery for glioblastoma in adults [J]. Brain Sci,2017, 7(12): 166-181.
[3] Zhu P, Zhu JJ. Tumor treating fields: a novel and effectivetherapy for glioblastoma: mechanism, efficacy, safety andfuture perspectives [J]. Chin Clin Oncol, 2017, 6(4): 41-55.
[4] Nidhi G, Aaron Y, Holtzman TS, et al. Tumor treating fieldsperturb the localization of septins and cause aberrant mitoticexit [J]. PloS One, 2015, 10(5): e0125269-e0125288.
[5] Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spin-dle disruption by alternating electric fields leads to impro-per chromosome segregation and mitotic catastrophe incancer cells [J]. Sci Rep, 2015, 5(1): 943-978.
[6] Wong ET, Lok E, Gautam S, et al. Dexamethasone exerts profound immunologic interference on treatment efficacy forrecurrent glioblastoma [J]. Br J Cancer, 2015, 113(11):1642.
[7] Giladi M, Schneiderman RS, Porat Y, et al. Mitotic disrup-tion and reduced clonogenicity of pancreatic cancer cells invitro and in vivo by tumor treating fields [J]. Pancreatology,2014, 14(1): 54-63.
[8] Schneiderman RS, Voloshin T, Giladi M, et al. ATPS-25p53 Status dependence of tumor treating fields (TTfields)efficacy against glioma cancer cells [J]. Neuro Oncol, 2015,17(suppl 5): v23-v23.
[9] Porat Y, Shteingauz A, Giladi M, et al. Abstract 3543: Alter-nating electric fields (TTFields) induce autophagy in humancancer cell lines [J]. Cancer Res, 2016, 76(14 Supplement):3543.
[10] Schneiderman RS, Shteingauz A, Giladi M, et al. Abstract 5078: Tumor treating fields (TTFields) reduce migrationand invasion properties of human glioma cancer cells invitro [J]. Cancer Res, 2016, 76(14 Supplement):5078.
[11] Lukas RV, Ratermann KL, Wong ET, et al. Skin toxicities associated with tumor treating fields: case based review [J].J Neurooncol, 2017, 135(3): 593-599.
[12] Voegeli D. Moisture-associated skin damage: an overviewfor community nurses [J]. Br J Community Nurs, 2013, 18(1): 6-10.
[13] Byrd AL, Belkaid Y, Segre JA. The human skin microbiome[J]. Nat Rev Microbiol, 2011, 9(4): 244-253.
[14] Clark PA, Gaal JT, Strebe JK, et al. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells [J]. JClin Neurosci, 2016, 36(suppl 6): 120-124.
[15] Alexiades N, Mckhann GM. A shock to the system: tumor-treating fields plus temozolomide for glioblastoma [J].Neurosurgery, 2018, 82(5): E115-E116.
[16] Akbarnejad Z, Eskandary H, Dini L, et al. Cytotoxicity oftemozolomide on human glioblastoma cells is enhanced bythe concomitant exposure to an extremely low-frequencyelectromagnetic field (100Hz, 100G) [J]. Biomed Pharmco-ther, 2017, 92: 254-264.
[17] Schneiderman RS, Shmueli E, Kirson ED, et al. TTFields alone and in combination with chemotherapeutic agentseffectively reduce the viability of MDR cell sub-lines thatover-express ABC transporters [J]. BMC Cancer, 2010, 10(1): 229-230.
[18] Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treat-ing fields plus maintenance temozolomide vs maintenancetemozolomide alone on survival in patients with glioblas-toma: a randomized clinical trial [J]. JAMA, 2017, 318(23):2306-2316.
[19] Guzauskas GF, Pollom EL, Stieber VW, et al. Tumor treatingfields and maintenance temozolomide for newly diagnosedglioblastoma: a cost-effectiveness study [J]. J Med Econ,2019, 22(10): 1.
[20] Trusheim J, Dunbar E, Battiste J, et al. A state-of-the-art review and guidelines for tumor treating fields treatmentplanning and patient follow-up in glioblastoma [J]. CNSOncology, 2017, 6(1): 29-43.
[21] Lacouture ME, Denigris J, Kanner AA. Supportive care inpatients using tumor treating fields therapy [M]. Switzer-land: Springer International Publishing, 2016. 103-116.